00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
20:05 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

FDA panel backs Janssen's fast-acting depression treatment

A lack of available treatment options swayed a 14-2 panel vote in favor of recommending approval of intranasal Spravato esketamine (formerly JNJ-54135419) from Janssen Pharmaceuticals Inc. to treat patients with treatment-resistant depression. If approved, Spravato...
18:21 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells...
00:23 , Feb 15, 2019 |  BC Innovations  |  Product R&D

A bug about Alzheimer’s

Cortexyme Inc. believes it has connected the dots between Alzheimer’s and gum disease, outlining a path from the bacteria that cause periodontitis to chronic brain infection with hallmarks of AD. But in a field that...
14:57 , Feb 14, 2019 |  BC Extra  |  Financial News

Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells...
23:21 , Feb 13, 2019 |  BC Week In Review  |  Company News

AbbVie gains option to Teneobio BCMA program

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset. TNB-383B targets BCMA and...
00:03 , Feb 13, 2019 |  BC Extra  |  Company News

FDA panel backs Janssen's fast-acting depression treatment

The lack of available treatment options swayed a 14-2 panel vote in favor of recommending approval of intranasal Spravato esketamine (formerly JNJ-54135419) from Janssen Pharmaceuticals Inc. to treat patients with treatment-resistant depression. If approved, Spravato...
22:23 , Feb 11, 2019 |  BC Extra  |  Company News

AbbVie gains option to Teneobio BCMA program

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset. TNB-383B targets BCMA and...
02:06 , Feb 9, 2019 |  BioCentury  |  Politics, Policy & Law

Killing Part D rebates

HHS’s proposal to scrap the secret rebates drug manufacturers pay PBMs and health plans in Medicare Part D would help President Donald Trump fulfill promises to reduce drug prices. It would also reduce financial burdens...
00:14 , Feb 9, 2019 |  BioCentury  |  Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...